SOLVD Health broadens AvertD access as FDA clears blood-based sample collection
FDA cleared blood-based collection for SOLVD Health’s AvertD. Find out why this could expand genetic opioid risk testing in surgical care.
Medical Devices & Diagnostics
Pharma & Biotech
How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape
Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.